Envista Holdings Corp (NVST) Income Statement Analysis

See more : AFC Ajax NV (AFCJF) Income Statement Analysis – Financial Results

Complete financial analysis of Envista Holdings Corp (NVST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Envista Holdings Corp, a leading company in the Medical – Equipment & Services industry within the Healthcare sector.

You may be interested

Samji Electronics Co., Ltd. (037460.KQ) Income Statement Analysis – Financial Results
Broadcom Inc. (1YD.DE) Income Statement Analysis – Financial Results
Beston Global Food Company Limited (BFC.AX) Income Statement Analysis – Financial Results
ACpay Co., Ltd. (6984.TWO) Income Statement Analysis – Financial Results
Shinhan Financial Group Co., Ltd. (055550.KS) Income Statement Analysis – Financial Results

Envista Holdings Corp (NVST)

Industry: Medical - Equipment & Services

Sector: Healthcare

Website: http://www.envistaco.com/

About Envista Holdings Corp

Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

Metric	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	2.57B	2.57B	2.51B	2.28B	2.75B	2.84B	2.81B	2.79B
Cost of Revenue	1.12B	1.09B	1.08B	1.12B	1.24B	1.24B	1.19B	1.18B
Gross Profit	1.45B	1.47B	1.43B	1.16B	1.51B	1.60B	1.62B	1.60B
Gross Profit Ratio	56.52%	57.41%	56.86%	50.75%	54.99%	56.31%	57.68%	57.48%
Research & Development	93.80M	100.10M	100.50M	100.80M	154.70M	172.00M	172.40M	142.80M
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.06B	1.06B	1.02B	1.02B	1.08B	1.13B	1.06B	1.06B
Other Expenses	268.30M	3.10M	2.40M	-900.00K	1.50M	2.70M	100.00K	-1.10M
Operating Expenses	1.42B	1.16B	1.12B	1.12B	1.24B	1.30B	1.23B	1.20B
Cost & Expenses	2.54B	2.25B	2.20B	2.25B	2.47B	2.55B	2.42B	2.38B
Interest Income	0.00	38.40M	54.10M	62.50M	3.50M	0.00	0.00	0.00
Interest Expense	63.40M	38.40M	54.10M	62.50M	3.50M	0.00	0.00	0.00
Depreciation & Amortization	162.60M	162.10M	151.90M	163.10M	168.10M	130.00M	121.40M	127.20M
EBITDA	171.10M	484.40M	460.50M	205.60M	447.10M	454.80M	508.10M	530.00M
EBITDA Ratio	6.67%	18.85%	18.35%	8.57%	10.14%	15.06%	18.08%	19.03%
Operating Income	31.50M	319.20M	306.20M	33.30M	110.90M	298.40M	386.60M	402.80M
Operating Income Ratio	1.23%	12.42%	12.20%	1.46%	4.03%	10.49%	13.75%	14.46%
Total Other Income/Expenses	-86.40M	-35.30M	-51.70M	-63.50M	39.80M	2.70M	100.00K	-1.10M
Income Before Tax	-54.90M	283.90M	254.50M	-30.10M	275.50M	301.10M	386.70M	401.70M
Income Before Tax Ratio	-2.14%	11.05%	10.14%	-1.32%	10.01%	10.59%	13.76%	14.42%
Income Tax Expense	45.30M	45.90M	-9.00M	-63.40M	57.90M	70.40M	85.60M	129.70M
Net Income	-100.20M	243.10M	263.50M	33.30M	217.60M	230.70M	301.10M	272.00M
Net Income Ratio	-3.90%	9.46%	10.50%	1.46%	7.91%	8.11%	10.71%	9.77%
EPS	-0.60	1.46	1.63	0.21	1.60	1.49	1.95	1.76
EPS Diluted	-0.60	1.34	1.48	0.20	1.60	1.49	1.95	1.76
Weighted Avg Shares Out	166.90M	162.90M	161.20M	159.60M	136.20M	154.60M	154.60M	154.60M
Weighted Avg Shares Out (Dil)	166.90M	177.60M	177.60M	164.10M	136.40M	154.60M	154.60M	154.60M

Envista Announces Participation in Baird's 2024 Global Healthcare Conference

August 27, 2024prnewswire.com

BREA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024 from 10:50 – 11:20 am ET at...

Envista: $1.2 Billion Asset Impairments Was Fully Priced In

August 16, 2024seekingalpha.com

Envista Holdings Corporation published Q2 2024 earnings results, highlighting a $1.2 billion non-cash charge from impairments. I find their valuation metrics quite attractive, comparing favorably to both the healthcare sector and their 5-year historical averages. Despite recent challenges, the company...

Why Envista (NVST) International Revenue Trends Deserve Your Attention

August 12, 2024zacks.com

Examine Envista's (NVST) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall

August 8, 2024zacks.com

Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.

Envista Holdings Corporation (NVST) Q2 2024 Earnings Call Transcript

August 7, 2024seekingalpha.com

Envista Holdings Corporation (NYSE:NVST ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Stephen Keller - Principal Financial Officer Paul Keel - CEO Eric Hammes - Incoming CFO Conference Call Participants Elizabeth Anderson - Evercore...